Emergent BioSolutions Inc. EBS R2K

Healthcare · Drug Manufacturers - Specialty & Generic · United States

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Market & Price

Market Cap

$470.56M

Current Price

$9.12

High / Low (52W)

$13.90 / $5.63

Beta

2.33

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

3.05

PEG Ratio

0.38

Book Value

$10.10

Price to Book

0.90

P/S

0.70

EV/EBITDA

5.37

Dividend Yield

Profitability & Returns

ROCE

11.98%

ROE

-1.60%

ROA

3.43%

Profit Margin

-1.27%

Op Margin

6.79%

EPS (Latest Qtr)

$0.07

EPS (TTM)

$-0.19

Balance Sheet & Liquidity

Debt/Equity

1.12

Quick Ratio

1.90

Current Ratio

4.29

Debt

$584.60M

Total Assets

$1.32B

Current Assets

$662.50M

Working Capital

$530.30M

Ownership

Promoter Holding

3.86%

Chg in Prom Hold

FII / Inst Holding

85.74%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$894.86M

Total Revenue (TTM)

$676.80M

EBITDA

$166.70M

Free Cash Flow

$256.21M

Operating Cash Flow

$148.00M

Shares Outstanding

51.60M

Gross Margin

47.49%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

-13.14%

Profit 5Y

41.62%

Revenue (YoY)

-29.70%

Earnings (YoY)

-93.80%

PROS

Profit CAGR of 41.6% over 5 years.
Generates positive free cash flow.

CONS

Revenue declined at -13.1% CAGR over 5 years.
Trading 34.4% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	EBS Emergent BioSolutions Inc. R2K	9.12	-	$470.56M	-	11.98%	-1.60%	-13.14%	41.62%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	116.90M	100.80M	149.40M	193.80M	117.80M	220.20M	173.70M	270.70M	190.60M	243.20M	311.80M	360.40M	192.50M	394.70M	385.20M	583.00M	343.00M	397.50M	-	-	-	-	-	-	-	300.40M	254.70M	-	-	209.10M	130.30M	222.00M	143.80M	149.70M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	88.50M	66.90M	85.90M	84.90M	72.00M
Gross Profit	63.16M	65.15M	21.16M	-2.04M	35.48M	50.93M	14.90M	8.50M	47.80M	53.10M	-9.50M	66.80M	21.30M	11.20M	-27.40M	-7.00M	70.70M	77.80M	-	-	-	-	222.40M	144.30M	94.60M	142.00M	65.60M	75.30M	4.90M	140.70M	87.20M	147.80M	-48.00M	-	-	120.60M	63.40M	136.10M	58.90M	77.70M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	70.70M	61.80M	59.60M	74.60M	67.20M
Operating Income	63.16M	49.89M	21.16M	-2.04M	35.48M	-	14.91M	8.53M	47.77M	-	-9.50M	66.80M	21.30M	-	-27.40M	-7.00M	70.70M	77.80M	-11.60M	126.00M	61.30M	258.10M	95.40M	14.50M	-34.70M	6.90M	-76.30M	-45.30M	-147.60M	-292.90M	-242.10M	39.80M	-203.50M	-	-	49.90M	1.60M	76.50M	-15.70M	10.50M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	132.80M	21.40M	96.20M	-12.50M	47.90M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.70M	14.70M	15.20M	14.70M	11.00M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	92.70M	-16.80M	57.60M	-50.70M	13.40M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24.70M	-4.80M	6.40M	3.90M	6.60M
Net Income	36.94M	33.35M	3.99M	-10.95M	21.34M	-	10.48M	4.62M	33.55M	-	-4.90M	50.10M	20.90M	-3.40M	-26.10M	-9.50M	43.20M	46.90M	-12.50M	92.70M	39.50M	185.40M	69.70M	4.60M	-32.70M	-4.60M	-52.90M	-87.10M	-186.20M	-261.40M	-263.40M	9.00M	-283.10M	-	-	68.00M	-12.00M	51.20M	-54.60M	6.80M
Diluted EPS	0.79	0.71	0.10	-0.27	0.45	0.77	0.23	0.11	0.68	-	-0.10	0.98	0.41	-0.07	-0.51	-0.18	0.83	0.90	-0.24	1.73	0.73	3.44	1.28	0.09	-0.61	-0.09	-1.06	-1.75	-3.71	-5.16	-5.08	0.17	-5.38	-	-	1.19	-0.22	0.91	-1.04	0.07
R&D Expense	34.18M	-	26.09M	27.89M	27.19M	-	20.48M	25.75M	22.66M	-	29.10M	24.70M	37.00M	-	46.10M	63.90M	53.40M	-	42.70M	47.90M	84.40M	-	52.50M	48.90M	49.60M	46.40M	49.80M	42.20M	40.70M	26.00M	15.30M	15.10M	32.70M	13.80M	-	15.10M	12.50M	13.50M	-	10.50M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	488.80M	560.90M	782.40M	1.11B	1.56B	-	1.08B	1.02B	1.01B	705.20M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	693.10M	705.40M	681.30M	326.20M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	916.30M	891.30M	383.00M	317.60M	332.30M	379.00M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	546.30M	519.10M	413.80M	266.70M
Operating Income	40.15M	73.56M	32.10M	29.97M	42.80M	89.19M	141.51M	105.50M	124.30M	89.80M	114.10M	433.80M	341.40M	-163.30M	-201.50M	-81.50M	112.30M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-38.40M	-518.20M	36.90M	237.90M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	37.30M	87.90M	71.00M	59.30M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-219.00M	-731.20M	-142.90M	82.80M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-7.40M	29.30M	47.70M	30.20M
Net Income	31.14M	51.70M	23.02M	23.52M	31.14M	36.74M	62.87M	51.80M	82.60M	62.70M	54.50M	305.10M	219.50M	-211.60M	-760.50M	-190.60M	52.60M
Diluted EPS	0.99	1.59	0.64	0.65	0.85	0.88	1.41	1.13	1.71	1.22	1.04	5.67	4.06	-4.47	-14.85	-3.60	0.93
R&D Expense	74.59M	89.30M	124.83M	120.23M	119.93M	104.72M	119.19M	106.90M	97.40M	142.80M	226.20M	234.50M	235.20M	188.30M	111.40M	70.70M	53.20M

Compounded Sales Growth

5 Years:	-13.14%
1 Year:	-29.70%

Compounded Profit Growth

5 Years:	41.62%
1 Year:	-93.80%

Stock Price Performance

1 Year:	+44.30%
6 Months:	-16.71%
3 Months:	+11.90%
1 Month:	+14.14%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	500.32M	546.86M	564.23M	626.63M	938.69M	1.04B	970.11M	1.07B	2.23B	2.33B	2.88B	-	3.17B	1.82B	1.39B	1.32B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.21B	679.50M	598.70M	662.50M
Cash & Equivalents	91.47M	102.92M	169.02M	143.90M	141.67M	179.34M	280.50M	312.80M	271.50M	178.30M	112.20M	167.80M	621.30M	-	642.60M	111.70M	99.50M	205.40M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	350.70M	328.90M	311.70M	343.40M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	102.70M	141.80M	135.40M	66.80M
Total Liabilities	-	-	126.76M	130.14M	122.10M	137.47M	385.49M	377.47M	373.91M	157.90M	1.22B	1.24B	1.44B	-	1.78B	1.17B	906.90M	796.00M
Current Liabilities	-	-	75.72M	71.05M	61.91M	56.65M	92.94M	99.61M	105.86M	100.10M	200.40M	216.30M	384.50M	-	1.23B	651.30M	162.40M	132.20M
Long Term Debt	-	-	30.24M	54.09M	58.30M	62.00M	251.00M	246.89M	248.09M	13.50M	784.50M	798.40M	841.00M	-	448.50M	446.50M	663.70M	572.10M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.41B	860.20M	663.70M	572.10M
Total Equity	-	-	369.46M	414.25M	441.36M	489.62M	553.20M	-	596.20M	912.30M	1.01B	1.09B	1.45B	-	1.39B	649.30M	482.80M	522.60M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	55.70M	57.80M	59.93M	60.80M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	29.87M	98.02M	12.19M	39.64M	96.97M	112.32M	42.52M	54.60M	208.10M	41.80M	188.00M	536.00M	-	-34.10M	-206.30M	58.70M	170.60M
Investing Cash Flow	-33.29M	-23.46M	-53.96M	-40.11M	-67.89M	-210.05M	-45.46M	-76.20M	-249.90M	-897.20M	-96.90M	-151.00M	-	-381.30M	212.30M	125.20M	69.40M
Financing Cash Flow	14.84M	-8.45M	16.66M	-1.76M	8.61M	198.87M	35.39M	-19.80M	-51.40M	788.70M	-35.90M	69.50M	-	481.20M	-535.70M	-190.00M	-136.60M
Capital Expenditure	-33.29M	-22.10M	-54.03M	-53.84M	-42.02M	-30.67M	-44.81M	-76.20M	-54.80M	-72.10M	-86.90M	-141.00M	-	-115.80M	-51.60M	-22.90M	-13.80M
Free Cash Flow	-3.42M	75.92M	-41.84M	-14.20M	54.95M	81.64M	-2.29M	-21.60M	153.30M	-30.30M	101.10M	395.00M	-	-149.90M	-257.90M	35.80M	156.80M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	65.80M	-529.70M	-6.10M	103.40M
Share Buybacks	-	0	0	5.91M	213.00K	200.00K	100.00K	0	33.10M	100.00K	0	0	106.00M	82.10M	0	0	24.90M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	58.9%	-	35.6%	31.0%	32.8%	53.7%
Operating Margin %	-	-	-	-	-	-	-	21.6%	22.2%	11.5%	10.3%	27.9%	-	-15.2%	-19.7%	-8.0%	15.9%
Net Margin %	-	-	-	-	-	-	-	10.6%	14.7%	8.0%	4.9%	19.6%	-	-19.7%	-74.3%	-18.8%	7.5%
ROE %	-	14.0%	5.6%	5.3%	6.4%	6.6%	-	8.7%	9.1%	6.2%	5.0%	21.0%	-	-15.2%	-117.1%	-39.5%	10.1%
ROCE %	-	17.3%	6.7%	6.0%	7.5%	10.5%	15.1%	12.2%	12.8%	4.4%	5.4%	17.4%	-	-8.4%	-17.2%	-6.6%	9.5%

Shareholding Pattern

Insiders

3.86%

Institutions

85.74%

Public Float

89.19%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	8.41%	4.34M	$39.59M
2	State Street Corporation	5.52%	2.85M	$25.99M
3	Dimensional Fund Advisors LP	5.34%	2.76M	$25.15M
4	American Century Companies Inc	4.70%	2.43M	$22.12M
5	Vanguard Capital Management LLC	4.38%	2.26M	$20.59M
6	Charles Schwab Investment Management, Inc.	2.92%	1.51M	$13.74M
7	Acadian Asset Management. LLC	2.68%	1.38M	$12.60M
8	Geode Capital Management, LLC	2.47%	1.27M	$11.61M
9	Palisade Capital Management, L.P.	2.33%	1.20M	$10.96M
10	Vanguard Portfolio Management LLC	2.17%	1.12M	$10.19M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for EBS

No recent headlines available.

EBS · Healthcare